The IVIG and SCIG Market in the United States in 2024 and Forecast to 2033
AN ANALYSIS OF THE 2024 United States INTRAVENOUS AND SUBCUTANEOUS IMMUNOGLOBULIN MARKET (IVIG & SCIG) AND FORECAST Through THE YEAR 2033
In recent years, the demand for IG has grown at >8% annually in the U.S. due to the addition of new patients treated, new medical indications, higher dosage, longer life expectancy, weight gains and other factors while prices have increased moderately. At the same time, the growing demand in emerging markets has also contributed to the market expansion, putting pressure on manufacturing and plasma collections. Today, IG remains the undisputable driver of the global plasma proteins market, from plasma collections to fractionation capacity expansion and financial health of the plasma fractionation companies.
Combining primary and secondary research, this study describe the United States 2024 IG market by three metrics: By all indications (30 categories), by route of administration (IVIG & SCIG) and by site of care. It then uses all this information and the view of experts to provide a yearly forecast of the demand through 2033 in kilograms and in dollars. It also provides a breakdown of IG use in grams by medical indication for each of these years from 2024 through 2033.
The report is a 240 page report which extensively covers current use of all uses of IG across diseases and makes extensive predictions about how each market will develop given novel competition and reactions by plasma companies in the coming years. Email us at info@marketingresearchbureau.com for a full Table of Contents and also for pricing of this report.
Table of Contents
Executive Summary
1. Introduction
2. Methodology & Assumptions
2.1 Research Resources
2.2 Market Analysis
2.3 Forecasting the Period 2025 to 2033
2.4 Selection of Diseases/Disease Categories
2.5 Comorbidities
3. 2021 Market Analysis
3.1 Total IG Market – Volume and Growth 2018-2024
3.2 IVIG and SCIG Market by Disease
3.3 Site of Care Analysis
3.4 IG Market by Medical Specialty
3.5 Average IG Usage per Patient & Number of Patients on each Therapy
3.6 Discussion of Key Diseases in 2024
3.6.1-3.6.18 Primary Immunodeficiency Diseases (PID), Secondary Immunodeficiency (SID), Chronic inflammatory demyelinating polyneuropathy (CIDP), Thrombocytopenia/ITP, Myasthenia gravis (Acute & Chronic), Solid Organ Transplant, Multifocal Motor Neuropathy (MMN), Neuropathy, Blood cancers, Dermatomyositis, GBS, Stiff Person Syndrome, Encephalitis, Myopathy, etc.
3.6.19 All Other Conditions
3.7 2021-2024 Average Growth and Contribution to Growth of Top Diseases
4. Forecast Methodology and Assumptions
4.1 Overall Forecast Assumptions
4.2 Assumptions about Competition in Key Diseases (FcRn and others)
5. 2033 Forecast Market Analysis
5.1 Total IG Market – Volume and Growth 2024-2033
5.2 Site of Care Future Expectations
5.3 Forecast of IG Market by Medical Specialty to 2033
5.4 Discussion of Key Diseases from 2024 to 2033
5.4.1-5.4.12 Primary Immunodeficiency Diseases (PID), Secondary Immunodeficiencies (SID), Chronic inflammatory demyelinating polyneuropathy (CIDP), Thrombocytopenia/ITP, Myasthenia gravis (Acute & Chronic), Solid Organ Transplant, Multifocal Motor Neuropathy (MMN), Neuropathy, Blood Cancers, Dermatomyositis, GBS, Stiff Person Syndrome, etc.
5.4.13 All Other Conditions
5.5 2024-2033 Average Growth and Contribution to Growth of Top Diseases
5.6 US IG Market by Dollar Value from 2024 to 2033